{"filing":{"accession_number":"0001104659-26-107253","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"tm2625289d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/tm2625289d1_8k.htm"},"events":[{"id":33104,"run_id":30428,"accession_number":"0001104659-26-107253","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Armata announced that the FDA granted Breakthrough Therapy designation to AP-SA02, a clinical-stage bacteriophage therapeutic for complicated S. aureus bacteremia. This regulatory milestone—combined with the company's existing Fast Track and QIDP designations—represents material operational progress that accelerates the development pathway and validates the therapeutic approach. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory and regulatory prospects.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36452,"accession_number":"0001104659-26-107253","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced that the FDA granted Breakthrough Therapy designation to AP-SA02, a clinical-stage bacteriophage therapeutic for complicated S. aureus bacteremia. This regulatory milestone—combined with the company's existing Fast Track and QIDP designations—represents material operational progress that accelerates the development pathway and validates the therapeutic approach. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:12:45.371593+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36452,"accession_number":"0001104659-26-107253","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced that the FDA granted Breakthrough Therapy designation to AP-SA02, a clinical-stage bacteriophage therapeutic for complicated S. aureus bacteremia. This regulatory milestone—combined with the company's existing Fast Track and QIDP designations—represents material operational progress that accelerates the development pathway and validates the therapeutic approach. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:12:45.371593+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-09-14"}]}